Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8<sup>+</sup> T cells.

Das, Jugal Kishore; Ren, Yijie; Kumar, Anil; Peng, Hao-Yun; Wang, Liqing; Xiong, Xiaofang; Alaniz, Robert C; de Figueiredo, Paul et al. · Sci Adv · 2022

basic_science · Level V

Where this comes from

Abstract

eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8<sup>+</sup> T cells. CD8<sup>+</sup> T cells from eEF-2K KO mice were more proliferative but had lower survival than their wild-type counterparts after their activation, followed by occurrence of premature senescence and exhaustion. eEF-2K KO CD8<sup>+</sup> T cells were more metabolically active and showed hyperactivation of the Akt-mTOR-S6K pathway. Loss of eEF-2K substantially impaired the activity of CD8<sup>+</sup> T cells. Furthermore, the antitumor efficacy and tumor infiltration of the CAR-CD8<sup>+</sup> T cells lacking eEF-2K were notably reduced as compared to the control CAR-CD8<sup>+</sup> T cells. Thus, eEF-2K is critically required for sustaining the viability and function of cytotoxic CD8<sup>+</sup> T cells, and therapeutic augmentation of this kinase may be exploited as a novel approach to reinforcing CAR-T therapy against cancer.

Medical subject headings